Phase II clinical study of CIM331 (hemodialysis)

Phase II clinical study of CIM331 in hemodialysis patients with pruritus.

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222909

Enrollment

Registered

2015-07-09

Start date

2015-07-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pruritus in dialysis patients

Interventions

investigational material(s) Generic name etc : CIM331 INN of investigational material : nemolizumab Therapeutic category code : 639 Other biological preparations Dosage and Administration for Investig

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients who receive hemodialysis three times a week. (2) Patients who have been treated with systemic therapy or topical therapy for pruritus and who are inadequately controlled by them, or patients who have been treated with nalfurafine hydrochloride for pruritus.

Exclusion criteria

Exclusion criteria: Patients who are judged to be inadequate for this study participation by investigator.

Design outcomes

Primary

Measure	Time frame
Pruritus visual analog scale	—

Secondary

Measure	Time frame
Shiratori's score etc.	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026